title: Pilot study of intra-arterial floxuridine, mitomycin and doxorubicin in combination with degradable starch microspheres to treat primary and metastatic tumors of the liver.
abstract: Concurrent administration of degradable starch microspheres and cytostatic agents into the hepatic artery results in decreased systemic exposure and increased hepatic exposure to drug compared to intra-arterial administration of drug alone. Degradable starch microspheres 210 mg/m2 mixed with floxuridine 500 mg/m2, doxorubicin 40 gm/m2, and mitomycin 10 mg/m2 were administered through hepatic artery catheters to eleven patients with primary or metastatic cancer of the liver. Toxicity was acceptable and consisted of severe myelosuppression (5%), duodenal/gastric ulceration (9%), mild to moderate nausea and vomiting (17%) and alopecia (86%). There were no responses among the eleven patients; 7 of 7 patients with colo-rectal carcinoma had stable disease while on study. Minimal activity was observed in 7 patients with colo-rectal carcinoma. The use of degradable starch microspheres offers a new approach to the regional treatment of cancer and warrants further study.
authors.forename: C E
authors.initials: CE
authors.lastname: Pfeifle
authors.forename: S B
authors.initials: SB
authors.lastname: Howell
authors.forename: J J
authors.initials: JJ
authors.lastname: Bookstein
mesh_terms: D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage / Q000627:therapeutic use*; D013213:Starch
chemical_list: D008937:Mitomycins; D005467:Floxuridine; D004317:Doxorubicin; D013213:Starch